AI tool could help liver cancer patients avoid ineffective therapy
NCT ID NCT07495735
First seen Apr 01, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study aims to build an artificial intelligence system that can predict whether a person with advanced liver cancer will respond to a common drug combination (atezolizumab and bevacizumab). Researchers will look back at medical records and CT scans from 400 patients to find patterns that show who benefits from treatment. The goal is to create a non-invasive tool that helps doctors choose the right therapy for each patient, avoiding unnecessary side effects and improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.